重组集成干扰素α体外抗病毒的药效学研究

Inhibitory effects of recombinant consensus interferon α on different viruses in vitro

目的:观察一种新型重组集成干扰素α(NIFN-conα)对流感病毒甲型和乙型、单纯疱疹病毒Ⅰ型和Ⅱ型、柯萨奇病毒B1和B3的抑制作用。方法:应用细胞病变抑制法,以已上市的重组集成干扰素α(干复津)及干扰素α作为阳性对照,观察不同浓度的NIFN-conα对不同病毒感染绿猴肾细胞(Vero)和狗肾细胞(MDCK)的抑制作用。结果:NIFN-conα对MDCK细胞和Vero细胞的TD50分别为(>250±0)μg/ml和(>192±0)μg/ml。对单纯疱疹Ⅰ型和Ⅱ型病毒的IC50分别是(2.8×10-4±8.5×10-5)和(1.8×10-4±8.5×10-5)μg/ml;对柯萨奇病毒B1和B3的IC50分别是(8.8×10-8±1.4×10-8)和(1.5×10-7±4.2×10-8)μg/ml,抑制流感病毒甲型和乙型的IC50分别是(2.5×10-2±1.2×10-2)和(>10±0)μg/ml。结论:NIFN-conα与干复津一样对单纯疱疹病毒、柯萨奇病毒和流感病毒均具有明显的抑制作用,与干扰素α相比,对流感病毒的抑制作用较弱,但对单纯疱疹病毒和柯萨奇病毒的抑制作用优于干扰素α。

Objective. To investigate the antiviml activity of one of the new recombinant consensus interferon α （NIFN-con α） in vitro, Methods： The cytopathic-effect inhibition assay was applied in this study to investigate the antiviral activity of this drug as well as the other IFN-con α （Infergen） and IFN-α as positive control. Vero cells and MDCK cells were infected by different viruses respectively and were cultured with serial dilutions of NIFN- con α. Results： The TD50 of NIFN-con α for MDCK cells and Veto cells was （ 〉 250± 0）μg/ml and 〉 192± 0 μg/ml, respectively. The IC50 of NIFN-con a for Herpes vires type 1 and type 2 was （2.8 × 10^-4 ± 8.5 × 10^-5 ） and （ 1.8 × 10^- 4 ± 8.5 × 10^- 5 ）μg/ml, respectively, for coxsackie virus B 1 and B3 was （8.8 × 10^-8s ± 1.4 × 10^- 8 ） and （ 1.5 × 10^- 7 ± 4.2 × 10^- 7 ） μg/ml, respectively and for influenza virus A and B was （2.5 × 10^- 2 ± 1.2 × 10^- 2 ） and （ 〉 10 ± 0）μg/ml, respectively. Conclusion： The new drug has similar antiviral activities with Infergen, and compare with interferon a, it has more effective antiviral activities for HSV and coxsackie virus except for influenza viruses.